Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells

Japanese Journal of Cancer Research

Volumn 93, Issue 12, 2002, Pages 1358-1365

  Chung, Sung Hwa ^a   Onoda, Naoyoshi ^a   Ishikawa, Tetsuro ^a   Ogisawa, Kana ^a   Takenaka, Chiemi ^a   Yano, Yoshihisa ^a   Hato, Fumihiko ^a   Hirakawa, Kosei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anaplastic thyroid cancer; p21; p27; p53; PPAR

Indexed keywords

LIGAND; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN J2; PROTEIN P21; PROTEIN P27; PROTEIN P53; TROGLITAZONE;

ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THYROID CANCER;

EID: 0036949695     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb01245.x     Document Type: Review

References (37)

1. Nel, C. J., van Heerden, J. A., Goellner, J. R., Gharib, H., McConahey, W. M., Taylor, W. F. and Grant, C. S. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases. Mayo Clin. Proc., 60, 51-58 (1995).
2. Demeter, J. G., De Jong, S. A., Lawrence, A. M. and Paloyan, E. Anaplastic thyroid carcinoma: risk factors and outcome. Surgery, 110, 956-963 (1991).
3. Venkatesh, Y. S., Ordonez, N. G., Schultz, P. N., Hickey, R. C., Goepfert, H. and Samaan, N. A. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 121 cases. Cancer, 66, 321-330 (1990).
4. Chawla, A., Schwarz, E. J., Dimaculangan, D. D. and Lazar, M. A. Peroxisome proliferator-activated receptor (PPAR) γ: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 135, 798-800 (1994).
5. Tontonz, P., Hu, E. and Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell, 79, 1147-1156 (1994).
6. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Wilson, T. M. and Kliewer, S. A. An antidiabetic thiazolidinedion is a high affinity ligand for peroxisome proliferator-activated receptor-γ (PPAR-γ). J. Biol. Chem., 270, 12953-12956 (1995).
7. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Wilson, T. M., Lenhard, J. M. and Lehmann, J. M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptor α and γ. Proc. Natl. Acad. Sci. USA, 94, 4318-4323 (1997).
8. 2 is a ligand for the adipocyte determination factor PPAR-γ. Cell, 83, 803-812 (1995).
9. 2 metabolite binds peroxisome proliferator activating receptor-γ and promotes adipocyte differentiation. Cell, 83, 813-819 (1995).
10. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M. and Spiegelman, B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA, 94, 237-241 (1997).
11. Demetri, G. D., Fletcher, C. D. M., Mueller, E., Sarraf, P., Naujoks, R., Campbell, N., Spiegelman, B. M. and Singer, S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl. Acad. Sci. USA, 96, 3951-3956 (1999).
12. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S. and Spiegelman, B. M. Terminal differentiation of human breast cancer through PPARγ. Mol. Cell, 1, 465-470 (1998).
13. Rubin, G. L., Zhao, Y., Kalus, A. M. and Simpson, E. Peroxisome proliferator-activated receptor γ ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res., 60, 1604-1608 (2000).
14. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Patridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C. and Spiegelman, B. M. Differentiation and reversal of malignant change in colon cancer through PPAR-γ. Nat. Med., 4, 1046-1052 (1998).
15. Kitamura, S., Miyazaki, Y., Shinomura, Y., Kondo, S., Kanayama, S. and Matsuzawa, Y. Peroxisome proliferator-activated receptor γ induces growth arrest and differentiation markers of human colon cancer cells. Jpn. J. Cancer Res., 90, 75-80 (1999).
16. Itami, A., Watanabe, G., Shimada, Y., Hashimoto, Y., Kawamura, J., Kato, M., Hosotani, R. and Imamura, M. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int. J. Cancer, 94, 370-376 (2001).
17. Ohta, K., Endo, T., Haraguchi, K., Hershman, J. M. and Onaya, T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab., 86, 2170-2171 (2001).
18. Ogisawa, K., Onoda, N., Ishikawa, T., Takenaka, C., Inaba, M., Ogawa, Y. and Hirakawa, K. Establishment and characterization of OCUT-1, an undifferentiated thyroid cancer cell line expressing high level of telomerase. J. Surg. Oncol., 80, 197-203 (2002).
19. Mukherjee, R., Jow, L., Croston, G. E. and Paterniti, J. R. Identification, characterization and tissue distribution of human (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem., 272, 8071-8076 (1997).
20. Kang, S. M., Maeda, K., Onoda, N., Chung, Y. S., Nakata, B., Nishiguchi, Y. and Sowa, M. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int. J. Cancer, 74, 502-507 (1997).
21. Osada, S., Tsukamoto, T., Takiguchi, M., Mori, M. and Osumi, T. Identification of an extended half-site motif required for the function of peroxisome proliferator-activated receptor α. Genes Cells, 2, 315-327 (1997).
22. Carmichael, J., DeGraff, W. G. and Gazdar, A. F. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47, 936-942 (1987).
23. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P. and Evans, R. M. The nuclear receptor superfamily: the second decade. Cell, 83, 835-839 (1995).
24. Ikezoe, T., Miller, C. W., Kawano, S., Heaney, A., Williamson, E. A., Hisatake, J., Green, E., Hofmann, W., Taguchi, H. and Koeffler, H. P. Mutational analysis of peroxisome proliferator-activated receptor-γ gene in human malignancies. Cancer Res., 61, 5307-5310 (2001).
25. Palmer, C. N., Hsu, M. H., Griffin, H. J. and Johnson, E. F. Novel sequence determinants in peroxisome proliferator signaling. J. Biol. Chem., 270, 16114-16121 (1995).
26. Katoh, R., Bray, C. E., Suzuki, K., Komiyama, A., Hemmi, A., Kawaoi, A., Oyama, T., Sugai, T. and Sasou, S. Growth activity in hyperplastic and neoplastic human thyroid determined by an immunohistochemical staining procedure using monoclonal antibody MIB-1. Hum. Pathol., 26, 139-146 (1995).
27. Morrison, R. F. and Farmer, S. R. Role of PPARγ in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis. J. Biol. Chem., 274, 17088-17097 (1999).
28. Wakino, S., Kintscher, U., Kim, S., Yin, F., Hsueh, W. A. and Law, R. E. Peroxisome proliferator-activated receptor γ ligands inhibit retinoblastoma phosphorylation and G1S transition in vascular smooth muscle cells. J. Biol. Chem., 275, 22435-22441 (2000).
29. Waldman, T., Kinzler, K. W. and Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res., 55, 5187-5190 (1995).
30. Haupt, Y., Rowan, S., Shaulian, E., Kazaz, A., Vousden, K. and Oren, M. p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia, 3, 337-339 (1997).
31. Haupt, Y. and Oren, M. p53-mediated apoptosis: mechanisms and regulation. Behring Inst. Mitt., 97, 32-59 (1996).
32. Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della, P. G. and Pierotti, M. A. P53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest., 91, 1753-1760 (1993).
33. Ito, T., Seyama, T., Mizuno, T., Tsuyama, N., Hayashi, T. and Hayashi, Y. Unique association of P53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res., 52, 1369-1371 (1992).
34. Nakamura, T., Yana, I., Kobayashi, T., Shin, E., Karakawa, K., Fujita, S., Miya, A., Mori, T., Nishisho, I. and Takai, S. p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn. J. Cancer Res., 83, 1293-1298 (1992).
35. Namba, H., Hara, T., Tukazaki, T., Migita, K., Ishikawa, N., Ito, K., Nagataki, S. and Yamashita, S. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res., 55, 2075-2080 (1995).
36. Kim, S. B., Ahn, I. M., Park, H. J., Park, J. S., Cho, H. J., Gong, G., Suh, C., Lee, J. S. Kim, W. K. and Kim, S. H. Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene. Head Neck, 23, 223-229 (2001).
37. Narimatsu, M., Nagayama, Y., Akino, K., Yasuda, M., Yamamoto, T., Yang, T. T., Ohtsuru, A., Namba, H., Yamashita, S., Ayabe, H. and Niwa, M. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J. Clin. Endocrinol. Metab., 83, 3668-3672 (1998).